Healthcare resource use and cost implications of low dose methoxyflurane for severe trauma-related pain: a qualitative study
Trauma (SAGE) · 2021-03-29 · Qualitative study
Abstract
Aims Management of moderate-to-severe trauma-associated pain is often reported as suboptimal, due in part to limitations associated with frequently used analgesics. Low-dose methoxyflurane (LDM) is an inhaled, non-opioid analgesic, recently approved for emergency relief of moderate-to-severe trauma-associated pain in conscious adults. This study assessed the perspective of healthcare professionals (HCPs) with regard to the time to analgesia and healthcare cost of LDM versus morphine IV, for patients with severe trauma-related pain receiving emergency care in Belgium. Materials and methods Interviews and questionnaires were completed by four healthcare HCPs providing emergency care at different hospitals in Belgium. Processes describing analgesic provision in pre-hospital and hospital emergency department (ED) settings were qualitatively mapped and a cost model applied which included reimbursed analgesic costs, time spent by HCPs making analgesic treatment decisions, preparing and administering the analgesic, and post-dose monitoring and management of analgesic-related adverse events (AEs). Results LDM was associated with substantial time and costs savings per patient, largely due to no requirement for AE monitoring. Compared with morphine IV, LDM in the hospital ED was associated with a time saving of 4 minutes to analgesic provision (35 vs 39 min) and ≥224 min in total (35 vs ≥259 min; including monitoring and managing AEs). In the pre-hospital setting, LDM was also associated with a time saving of 4 minutes to analgesic provision (21 vs 25 min) and 198 minutes in total. The corresponded total cost savings with LDM vs morphine IV were ≥€27.32 and ≥€17.95 in the ED or prehospital setting, respectively. Conclusions The cost model showed that LDM was associated with substantial time and costs savings versus morphine IV for severe trauma-related emergency pain in pre-hospital and hospital ED settings in Belgium.
Abstract © the authors or publisher, via OpenAlex. Reuse and removal
Tags
Analgesics · Cost & cost-effectiveness · Methoxyflurane · Morphine · Time intervals
Related articles
- Clinical effectiveness and costs of pre-hospital inhaled methoxyflurane for acute pain in trauma in adults: non-randomised control group study. (Br Paramed J, 2021)
- Evaluation of the effectiveness and costs of inhaled methoxyflurane versus usual analgesia for prehospital injury and trauma: non-randomised clinical study. (BMC Emerg Med, 2022)
- MetoksyKval: the extent of pre-hospital methoxyflurane administration for acute traumatic pain: focus on economic impact and rationale for use. (Scand J Trauma Resusc Emerg Med, 2026)
- Inhaled Methoxyflurane versus Intravenous Morphine for Severe Trauma Pain in the Emergency Setting: Subgroup Analysis of MEDITA, a Multicenter, Randomized, Controlled, Open-Label Trial. (J Pain Res, 2020)
- Analgesic Efficacy, Practicality and Safety of Inhaled Methoxyflurane Versus Standard Analgesic Treatment for Acute Trauma Pain in the Emergency Setting: A Randomised, Open-Label, Active-Controlled, Multicentre Trial in Italy (MEDITA). (Adv Ther, 2019)
- Evaluation of pain relief treatment and timelines in emergency care in six European countries and Australia. (Open Access Emerg Med, 2019)